Apnimed, Inc. Net Fee Amt
Apnimed, Inc. (APMD) had Net Fee Amt of $9.15 thousand as of 2026-09-08, per its S-8 filed 2026-09-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-08
- 2026-09-08: Net Fee Amt $9.15K.
- 2026-07-31: Net Fee Amt $20.47K.
- 2026-07-30: Net Fee Amt $5.08K.
- 2026-07-27: Net Fee Amt $11.60K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-08 | $9.15K S-8 · filed 2026-09-08 |
| 2026-07-31 | $20.47K S-8 · filed 2026-07-31 |
| 2026-07-30 | $5.08K S-1MEF · filed 2026-07-30 |
| 2026-07-27 | $11.60K S-1/A · filed 2026-07-27 |
| 2026-07-09 | $13.81K S-1 · filed 2026-07-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B |